Abstract:
Objective:The treatment of Pulmonary Tuberculosis patients with the combination of KangfengXin liquid and thymus pentapeptide.To observe the clinical curative effect and its effect on serum CXCL-10、FIB level.Methods:From April 2015 to April 2017, 140 patients with TB-PCR positive or sputum smear positive pulmonary tuberculosis treated in our hospital were selected.Randomly divided into control group (n = 70) and study group (n = 70).During the first two months of treatment, patients in the study group were given rifampicin, isoniazid, ethambutylamine, pyrazinamide, a new solution for the rehabilitation of thymosin enteric-coated tablets.The control group was given rifampicin isoniazid ethambutylaminepyrazinamide.Two months later, the study group and the control group were treated with rifampicin isoniazid for 4 months.To observe the clinical curative effect and the incidence of adverse reaction in the course of treatment.The indexes of immune function (CD8+, CD4+, CD3+ and CD4+/CD8+), CXCL-10 and FIB levels were compared between the two groups before and after treatment. Results:The clinical effective rate was 88.57 in the study group and 75.71 in the control group.The clinical effective rate of the study group was significantly higher than that of the control group (P < 0.05).After treatment, CXCL-10、FIB、CD8+ decreased significantly in both groups (P < 0.05).The study group was significantly lower than the control group (P < 0.05).The CD4+、CD3+、CD4+/CD8+ was significantly increased in both groups (P < 0.05), and was significantly higher in the study group than that in the control group (P < 0.05). Conclusion:The combination of KangfengXin liquid and thymus pentapeptide in the treatment of pulmonary tuberculosis has a good clinical effect, can significantly reduce the inflammatory reaction of patients, improve the immune function of patients, and high safety, can be popularized in clinical application